GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starton Therapeutics Inc (NAS:STA) » Definitions » EBIT

Starton Therapeutics (Starton Therapeutics) EBIT : $-7.63 Mil (TTM As of Jun. 2023)


View and export this data going back to 2050. Start your Free Trial

What is Starton Therapeutics EBIT?

Starton Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2023 was $-3.05 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was $-7.63 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Starton Therapeutics's annualized ROC % for the quarter that ended in Jun. 2023 was -274.97%. Starton Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -792.72%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Starton Therapeutics EBIT Historical Data

The historical data trend for Starton Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starton Therapeutics EBIT Chart

Starton Therapeutics Annual Data
Trend Mar21 Mar22 Mar23
EBIT
-9.21 -11.93 -9.99

Starton Therapeutics Quarterly Data
Mar21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23
EBIT Get a 7-Day Free Trial -3.29 -2.87 -2.21 -2.37 -3.05

Competitive Comparison of Starton Therapeutics's EBIT

For the Biotechnology subindustry, Starton Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Starton Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Starton Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Starton Therapeutics's EV-to-EBIT falls into.


Starton Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Starton Therapeutics  (NAS:STA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Starton Therapeutics's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

ROC % (Q: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2023 ) + Invested Capital (Q: Jun. 2023 ))/ count )
=-12.196 * ( 1 - 0.1% )/( (4.446 + 4.416)/ 2 )
=-12.183804/4.431
=-274.97 %

where

Invested Capital(Q: Mar. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2.137 - 3.54 - ( 0.142 - max(0, 6.005 - 0.156+0.142))
=4.446

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4.243 - 4.516 - ( 1.345 - max(0, 7.003 - 2.314+1.345))
=4.416

Note: The Operating Income data used here is four times the quarterly (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Starton Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2023  Q: Jun. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-12.196/( ( (1.564 + max(-5.83, 0)) + (1.513 + max(-5.877, 0)) )/ 2 )
=-12.196/( ( 1.564 + 1.513 )/ 2 )
=-12.196/1.5385
=-792.72 %

where Working Capital is:

Working Capital(Q: Mar. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.014) - (3.54 + 0 + 2.304)
=-5.83

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.969) - (4.516 + 0 + 2.33)
=-5.877

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Starton Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2023 )
=-7.632/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Starton Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Starton Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Starton Therapeutics (Starton Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starton Therapeutics Inc (NAS:STA) » Definitions » EBIT
Comparable Companies
Traded in Other Exchanges
N/A
Address
215 College Road, Suite No.300, Paramus, NJ, USA, 07652
Website
https://www.startontx.com
Starton Therapeutics Inc is a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer can receive continuous treatment to live better, and longer. Starton's proprietary continuous delivery technology can increase the efficacy of approved drugs, make them more tolerable, and expand their potential use.

Starton Therapeutics (Starton Therapeutics) Headlines

No Headlines